Literature DB >> 12866139

Angiogenesis and cancer: recent advances.

William Cáceres1, Samuel González.   

Abstract

Recent studies have shown the possibility to treat cancer with drugs that affect the formation of new blood vessels instead of attacking directly the malignant cell. This relatively new field in the area of oncology on angiogenesis inhibition has expanded the therapeutic option for malignant diseases. We will discuss several antiangiogenesis drugs in clinical development and their mechanism of action. Some of these drugs include: angiostatin, metalloproteinase inhibitors, thalidomide, tamoxifen, interferons and others. The use of antiangiogenic agents, both in combination with other treatment modalities in the acute setting as well as long-term maintenance or prevention of cancer, is at present one of the better promises in the war against cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12866139

Source DB:  PubMed          Journal:  P R Health Sci J        ISSN: 0738-0658            Impact factor:   0.705


  5 in total

1.  Effects of the angiogenesis inhibitor angiostatin on the growth of CC531 colon carcinoma cells in vitro and in a laparoscopic animal model of peritoneal carcinomatosis.

Authors:  G Nestler; H U Schulz; J Tautenhahn; R Kuhn; S Krüger; H Lippert; M Pross
Journal:  Int J Colorectal Dis       Date:  2005-10-05       Impact factor: 2.571

2.  Expression of angiostatin cDNA in human gallbladder carcinoma cell line GBC-SD and its effect on endothelial proliferation and growth.

Authors:  Ding-Zhong Yang; Jing He; Ji-Cheng Zhang; Zuo-Ren Wang
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

3.  Effects of recombinant human canstatin protein in the treatment of pancreatic cancer.

Authors:  Xiao-Ping He; Zhao-Shen Li; Ren-Min Zhu; Zhen-Xing Tu; Jun Gao; Xue Pan; Yan-Fang Gong; Jing Jin; Xiao-Hua Man; Hong-Yu Wu; Ai-Fang Xu
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

Review 4.  Tamoxifen non-estrogen receptor mediated molecular targets.

Authors:  Tatiana Bogush; Evgeny Dudko; Elena Bogush; Boris Polotsky; Sergei Tjulandin; Mikhail Davydov
Journal:  Oncol Rev       Date:  2012-10-04

Review 5.  Tamoxifen and oxidative stress: an overlooked connection.

Authors:  Nermin S Ahmed; Marek Samec; Alena Liskova; Peter Kubatka; Luciano Saso
Journal:  Discov Oncol       Date:  2021-05-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.